The FDA has approved Foundation Medicine’s liquid biopsy blood test, allowing oncologists to profile the genomic mutations found within any solid tumor without needing to remove and analyze small ...

Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer ...

--Landmark approval advances personalized cancer care as an estimated 1 in 3 patients across five common advanced cancers are expected to match with an FDA-approved therapy-- CAMBRIDGE, ...

A lipid profiling blood test may predict the risk for type 2 diabetes and CVD years in advance, according to findings published in PLOS Biology. “The lipidomic risk, which is derived from only one ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential ...

Only blood test approved by FDA as companion diagnostic for ORSERDU™ (elacestrant), Guardant360 CDx gains coverage by Aetna and Humana to identify eligible patients with advanced breast cancer prior ...

Oncotarget published "Analytic validation and clinical utilization of the comprehensive genomic profiling test, GEM ExTra®" which reported that the authors developed and analytically validated a ...

GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFILING TEST WITH COMPREHENSIVE MULTIOMIC ANALYSIS TO PROVIDE A MORE COMPLETE VIEW OF CANCER Powered by Guardant Infinity smart ...